Waters Corporation

Waters Corporation is an American life sciences tools and diagnostics company that designs, manufactures, and services high-performance liquid chromatography, mass spectrometry, thermal analysis, and — following its February 2026 acquisition of BD's Biosciences and Diagnostic Solutions businesses — flow cytometry, microbiology, and molecular diagnostics instruments and consumables, generating $3.2 billion in revenue in fiscal 2025 and a projected $6.4 billion on a combined basis in 2026.

This is a story about a company that spent five years methodically transforming itself from a dependable but cyclical analytical instruments manufacturer into one of the industry's best growth-and-margin stories, and then on 9 February 2026, closed a $16.8 billion acquisition that roughly doubled its size, added four new operating segments, and loaded the balance sheet with over $5 billion in debt. The Waters that reports its first full quarter as a combined company this summer is fundamentally a different enterprise from the one that filed its 2025 10-K — broader in scope, higher in leverage, and dependent for its near-term equity story on management's ability to repeat on the acquired businesses the operational playbook that worked on the legacy one.

The file turns on a single question: whether the revitalisation plan Udit Batra's team launched within days of the BD close — the "180-day plan" of funnel discipline, pricing rigour, commercial intensity, and China localization — can convert two declining businesses into growers before the instrument replacement cycle that has been lifting the legacy Waters operation begins to mature. Early data is encouraging. Organic legacy revenue grew 11% in constant currency in the first quarter of 2026; the acquired businesses delivered 7% estimated growth in the owned period versus expectations of low single digits. But three months of execution does not settle a debate that will take years to resolve.